Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ECOR vs RCEL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RCEL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

RCEL Overall Winner 6-Pillar Tally: ECOR 2 – 3 RCEL (1 Tie) Matrix Metrics: ECOR 3 – 7 RCEL

As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ECOR carries a Unified Composite Score of 44.5/100 (HOLD) at $4.42 (N/M Forward P/E, -33.1% operating margin), whereas RCEL carries 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin).

  • Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3); meanwhile RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ECOR vs RCEL
ECOR NASDAQ
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
-8.87% 1D
Market Cap $44.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.55β · 155% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 30.0 Fund 60.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.1%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.77 · SMA50: $8.56
RCEL NASDAQ Head-to-Head Winner
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.62
-2.31% 1D
Market Cap $506.7M
TTM Revenue $85M
Forward P/E 10.3x
Beta / 30D Vol 1.54β · 65% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 32.0 Fund 44.0 Flow 69.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (21.1% over 20 days), RSI 52
RSI-14: 51.5 · SMA20: $16.14 · SMA50: $13.96

6-Pillar Scorecard Institutional Category Breakdown (ECOR 2 – 3 RCEL)

Columns: Metric · ECOR · RCEL
1. Valuation Multiples RCEL
Forward P/E N/M 10.3x
Trailing P/E N/M 10.3x
PEG Ratio N/M N/M
EV / Revenue 1.3x 6.4x
2. Growth & Scale RCEL
Revenue Growth (YoY) +11.5% +53.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $38M $85M
Market Cap $44.7M $506.7M
3. Profitability & Quality ECOR
Gross Margin 87.7% 82.4%
Operating Margin -33.1% -33.9%
Net Profit Margin -33.5% -42.6%
Return on Equity (ROE) -478.7% -1746.3%
4. Balance Sheet & Cash Flow ECOR
Cash Generation (TTM) -$6.9M -$20M
Cash Flow Margin -18.1% -23.6%
Net Cash / Leverage $4.6M Net Debt $37M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RCEL
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 84.7% (6th %ile)
Put/Call OI Skew N/A 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ECOR (3) vs RCEL (7)
Institutional Metric ECOR RCEL Criterion Row Edge
Market Capitalization
Scale
$44.7M $506.7M Larger Scale RCEL
Trailing P/E Ratio
Valuation
N/M 10.3x Lower Multiple RCEL
Forward P/E Ratio
Valuation
N/M 10.3x Lower Multiple RCEL
Revenue Growth (YoY)
Growth
+11.5% +53.1% Higher Growth RCEL
Operating Margin (TTM)
Profitability
-33.1% -33.9% Higher Margin ECOR
Net Profit Margin
Profitability
-33.5% -42.6% Higher Margin ECOR
Return on Equity (ROE)
Capital Efficiency
-478.7% -1746.3% Higher ROE ECOR
52-Week Range Position
Momentum
6% ($4–$13) 82% ($3–$18) Stronger Trend RCEL
Beta / 30D Volatility
Risk Regime
1.55β · 155% Vol 1.54β · 65% Vol Lower Realized Risk RCEL
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 45.6 / 100 (HOLD) Higher Composite RCEL
Trailing 12M Revenue (USD)
Operating Scale
$38M $85M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% 82.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.3x EV/Rev N/M PEG · 6.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.9M ($4.6M Net Debt) -$20M ($37M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RCEL +41.65 pp
ECOR: -40.35% · RCEL: +1.3%
3M Horizon RCEL +111.82 pp
ECOR: -54.2% · RCEL: +57.62%
6M Horizon RCEL +274.78 pp
ECOR: -33.73% · RCEL: +241.05%
1Y Horizon RCEL +304.87 pp
ECOR: -9.43% · RCEL: +295.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ECOR Revenue RCEL Revenue ECOR Op. Margin RCEL Op. Margin Margin Leader
FY2018 $0M $0M -5494.1% -1489.9% RCEL
FY2019 $0M $10M -1928.2% -466.4% RCEL
FY2020 $0M $10M -707.9% -299.2% RCEL
FY2021 $10M $30M -367.7% -90.8% RCEL
FY2022 $10M $30M -266.2% -79.9% RCEL
FY2023 $20M $50M -120.2% -85.1% RCEL
FY2024 $30M $60M -48.3% -88.1% ECOR
FY2025 $30M $70M -41.1% -59.4% ECOR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RCEL CONSOLIDATION
17d in phase · OBV NEUTRAL
Current IV 84.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $44.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RCEL Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $506.7M market capitalization and -33.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ECOR vs RCEL Key Questions & Quantitative Answers

As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ECOR carries a Unified Composite Score of 44.5/100 (HOLD) at $4.42 (N/M Forward P/E, -33.1% operating margin), whereas RCEL carries 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin). Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3); meanwhile RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RCEL leads the Growth & Scale pillar: ECOR posts +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin), compared with RCEL at +53.1% YoY revenue growth and +0.0% YoY earnings growth on $85M TTM revenue (82.4% gross margin, -33.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ECOR cumulative revenue shifted +200.0% while RCEL shifted +600.0%. In operating R&D and SG&A reinvestment, ECOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCEL.

RCEL screens cheaper on headline valuation multiples. ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-18.1% FCF margin), whereas RCEL trades at 10.3x Forward P/E, 10.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-23.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECOR (-478.7% ROE) versus RCEL (-1746.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 155% Vol realized risk). By comparison, RCEL carries 84.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.54β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.